Closely-held Scientus Pharma, through its HydRx Farms unit, has entered into a major wholesale purchase agreement with Aphria (TSX:APH; OTCQB:APHQF).
Under the accord, Aphria would supply more than 25,000 fully-grown medical cannabis plants over the next 12 months to Scientus.
Leveraging its patent-pending formulation and processing technologies, Scientus is leading the medical cannabis market towards pharmaceutical standards in manufacturing, formulations and dosing.
In a statement, Vic Neufeld, CEO of Aphria, said that through this agreement, Scientus would receive clean and safe cannabis, which is necessary in the biopharmaceutical cannabis industry.
Trevor Folk, CEO of Scientus, said the company’s extraction technology platform has solved the resin consistency issue that has here-to-for prevented scientific advancement of cannabinoid products, and it is the “foundation for Scientus Pharma’s pipeline of novel products.”
